NCT02199665View on ClinicalTrials.gov

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 12, 2014

Primary Completion Date

July 31, 2026

Study Completion Date

December 25, 2026

Conditions
Refractory Multiple Myeloma
Interventions
DRUG

selinexor

Given PO

DRUG

carfilzomib

Given IV

DRUG

dexamethasone

Given PO or IV

Trial Locations (5)

10029

RECRUITING

Mount Sinai Medical Center, New York

48109

ACTIVE_NOT_RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

RECRUITING

Wayne State University Karmanos Cancer Institute, Detroit

60637

RECRUITING

University of Chicago, Chicago

85259

ACTIVE_NOT_RECRUITING

Mayo Clinic (AZ), Scottsdale

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER